It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University Medical Center Utrecht, Department of Neurology, Brain Center Rudolf Magnus, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
2 University of Torino, Rita Levi Montalcini’ Department of Neuroscience, ALS Centre, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
3 KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven, Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); VIB, Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); University Hospitals Leuven, Department of Neurology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)
4 Academic Unit of Neurology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705); Department of Neurology, Beaumont Hospital, Dublin, Ireland (GRID:grid.414315.6) (ISNI:0000 0004 0617 6058)
5 Population Genetics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705)
6 University of Würzburg, Institute of Clinical Neurobiology, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
7 Ulm University, Department of Neurology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
8 ALS Unit, Hospital San Rafael, Madrid, Spain (GRID:grid.6582.9)